Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Trillium Therapeutics Inc. T.TRIL

Trillium Therapeutics Inc is a clinical-stage immuno-oncology company that is engaged in developing therapies for the treatment of cancer. It has two clinical programs, TTI-621 and TTI-622, that target CD47. The company operates in the United States and Canada.


TSX:TRIL - Post by User

Comment by BJohnson1979on Mar 05, 2020 3:47pm
264 Views
Post# 30772100

RE:47 got 4.9B

RE:47 got 4.9BK so 47 doubling in cap from $2.25 Billion to $4.5 Billion is great because Trillium's cap right now, meaning factoring in the pop on the Gilead deal is ~ $700 million. Explain to me why you'd be a seller??? If my back of the envelope math is even remotely correct you'd talking $20. Yes/no?
<< Previous
Bullboard Posts
Next >>